

Elizabeth A. Handorf

[linkedin.com/in/elizabeth-handorf-64b971](https://www.linkedin.com/in/elizabeth-handorf-64b971) | github.com/BethHandorf

POSITIONS

Rutgers University New Brunswick, NJ

- Associate Professor, *Department of Biostatistics and Epidemiology* 2023 - current

Fox Chase Cancer Center, Temple University Health System Philadelphia, PA

- Associate Research Professor, *Biostatistics and Bioinformatics Facility* 2020 - 2023
- Assistant Research Professor, *Biostatistics and Bioinformatics Facility* 2014 - 2020
- Instructor, *Biostatistics and Bioinformatics Facility* 2012 - 2014

University of Pennsylvania, Perelman School of Medicine Philadelphia, PA

- Research Assistant, *Center for Comparative Effectiveness in Genomic Medicine* 2010 - 2011
- Research Assistant, *Center for Clinical Epidemiology and Biostatistics* 2008 - 2009

The Vanguard Group Malvern, PA

- Web Data Analyst 2007 - 2008
- Information Systems Engineer 2005 - 2007

EDUCATION

University of Pennsylvania, Perelman School of Medicine Philadelphia, PA

Doctor of Philosophy, Biostatistics 2012

- **Dissertation Topic:** Statistical methods for cost-effectiveness analysis using observational data

Master of Science, Biostatistics 2010

- **Masters Thesis:** Candidate gene study for renal function in liver transplant patients

University of Pennsylvania, School of Engineering and Applied Sciences Philadelphia, PA

Bachelor of Science in Engineering, Systems Engineering 2005

- Graduated magna cum laude
- **Focus:** Computer systems, **Minor:** Cognitive Science

TEACHING

Fox Chase Cancer Center

- **Lecturer:** Summer Cancer Research Institute – Biostatistics and Bioinformatics 2023
- **Lecturer:** Responsible Conduct in Research Training – Powered-studies and data-interpretation misconduct (P-hacking) 2023
- **Workshop leader:** Practical data analysis and visualization for laboratory scientists 2019
- **Lecturer:** Clinical research/trials course, Continuous data 2018
- **Lecturer:** Biostatistics orientation session 2013

Temple University

- **Lecturer:** Temple Urology Grand Rounds: Basic Biostatistics for the Urologist 2021
- **Lecturer:** Biomedical Sciences Graduate Program (BMSC8203) 2013 - 2018

University of Pennsylvania

- **Teaching Assistant:** Robert Wood Johnson Clinical Scholars Program 2009 - 2011

NATIONAL COMMITTEE SERVICE:

International Biometrics Society (IBS) Eastern North American Region (ENAR)

- 2023 Spring Meeting Program Committee Chair 2022 - 2023
- 2022 Spring Meeting Program Committee Member 2021 - 2021
- Liaison to the Council for Emerging and New Statisticians 2017 - 2020
- Regional Advisory Board member 2017 - 2020
- 2017 Spring Meeting Curriculum Committee Member 2016 - 2017

American Statistical Association

- Statistics in Epidemiology Section Council of Sections Representative 2024 - 2026

National Comprehensive Cancer Network

- Imaging AUC Resource Committee 2020 - 2023

EXTERNAL GRANT REVIEWS AND STUDY SECTIONS

Department of Defense

- FY22 Tuberos Sclerosis Complex Research Program (TSCR). Biostatistical Reviewer 2022
- FY22 Prostate Cancer Research Program (PCRP). Biostatistical Reviewer 2022
- FY21 Chronic Pain Management Research Program (CPMRP). Biostatistical Reviewer 2021
- FY20 Hearing Restoration Research Program. Biostatistical Reviewer 2021

National Aeronautics and Space Administration

- Directed study reviewer 2021
- Human Research Program Research Opportunities Sensorimotor Panel. Biostatistical Reviewer. 2020

Non-Federal organizations

- GMaP Region 4 Pilot studies reviewer 2020
- NCCN Pfizer Axitinib Scientific Review Committee. Biostatistical Reviewer 2020

EDITORIAL POSITIONS

Statistical Reviewer

- International Journal of Biostatistics 2023
- Journal of the National Cancer Institute 2023
- Gastroenterology 2022 - 2023
- Urologic Oncology 2020 - 2022
- Journal of the National Comprehensive Cancer Network 2017 - 2022
- Frontiers in Oncology 2022
- CardioOncology 2022
- BMC Cancer 2021
- Observational Studies 2021
- Statistics in Medicine 2015 - 2021
- Translational Behavioral Medicine 2017 - 2021
- Frontiers in Genetics 2019
- Electronic Journal of Statistics 2018
- Lung Cancer 2018
- PLOS One 2013 - 2018
- Journal of the American Statistical Association 2017 - 2018

- Endocrine Practice 2017
- Journal of Orthopaedic Trauma 2017
- Health Economics 2015 - 2016
- Cancer Genetics 2012 - 2015
- Value in Health 2014 - 2015
- Nicotine and Tobacco Research 2010 - 2011

ACADEMIC COMMITTEES

Fox Chase Cancer Center

- Research Review Committee, Statistical Reviewer 2012 - 2023
- In Vino Vitae Young Investigator Award review committee 2021 - 2023
- Summer Cancer Research Institute Reviewer 2021 - 2022
- Committee to Phase Back Science (Covid-19) 2020
- Translational Clinical Protocol Development Review Panel 2018
- Quantitative Science Seminar Series Organizer 2017 - 2019
- ACS-IRG Review Committee Member 2017
- Cancer Genome Institute Grant Review Panel 2013

FEDERAL AGENCY FUNDING HISTORY

1. AHRQ R03 HS029223 (PI: Handorf) 9/1/2022 - 8/31/2024
 Role: Principal Investigator
 Modeling Therapy Sequence for Advanced Cancer: A Microsimulation Approach Using Real-World Data
2. NIH R01 CA269660 (PI: Cukierman) 6/1/2022 - 6/15/2023
 Role: Biostatistician
 Pancreatic Cancer-Associated Fibroblasts: Function, Detection, and Regulation
3. DOD W81XWH-22-1-0368 (PI: Lynch) 6/1/2022 - 6/15/2023
 Role: Biostatistician
 Impact of Social Determinants of Health on Quality of Life and Treatment-related Decision-making in Advanced Prostate Cancer
4. NIH R21 CA252535 (PI: Astsaturov/Dotan) 8/1/2021 - 6/15/2023
 Role: Biostatistician
 Neoadjuvant Stroma Modification in Pancreatic Cancer (Multi-PI)
5. NIH P50 CA236762 (PI: Burtness, Yale Univ.) 4/1/2020 - 6/15/2023
 Role: Biostatistician
 Yale head and neck cancer SPORE: Overcoming treatment resistance in head and neck cancer
6. NIH R01 CA248655 (PI: Fang/Ma, Temple Univ.) 4/1/2020 - 6/15/2023
 Role: Biostatistician
 Evidence-Based Approach to Empower Asian American Women in Cervical Cancer Screening
7. R01 CA248655 Supp (PI: Fang/Ma) PI: Fang/Ma, Temple Univ.) 4/1/2022 - 3/31/2023
 Role: Biostatistician
 The major goal of this supplement is to compare rates of providing a self-collected sample vs. obtaining clinic-based cervical cancer screening among 150 Chinese American women with LEP.
8. NIH R03 CA219722 (PI: Vijayvergia) 1/1/2020 - 12/31/2021
 Role: Biostatistician
 Systematic study of variations in imaging techniques and response criteria for well differentiated pancreatic neuroendocrine tumors

9. NIH R01 CA222124 (PI: Reese) 9/4/2018 - 6/15/2023
 Role: Biostatistician
 Addressing sexual concerns in breast cancer survivors: RCT of a novel couple-based intervention
10. NIHU54 CA221705 (PI: Ma, G., Temple) 9/19/2018 - 6/15/2023
 Role: Biostatistician
 Temple University Fox Chase Cancer Center/Hunter College Regional Comprehensive Cancer Health
 Disparity Partnership
11. NIH P30 CA006927 (PI: Chernoff) 8/12/2016 - 6/15/2023
 Role: Biostatistician
 Comprehensive Cancer Center Program at Fox Chase
12. NIH R03 CA235238 (PI: Reese) 2/1/2019 - 1/31/2021
 Role: Biostatistician
 Enhancing breast cancer clinicians' communication about sexual health: A mobile technology-based
 (mLearning) intervention
13. NIH R01 CA194263 (PI: Fang / Campbell) 1/1/2016 - 12/31/2020
 Role: Biostatistician
 Understanding psychosocial and immunologic responses in indolent lymphoproliferative disorders
14. NIH R01 CA188430 (PI: Astsaturov) 9/19/2014 - 8/31/2020
 Role: Biostatistician
 Synergistic targeting of cholesterol metabolism and EGFR signaling in cancer
15. NIH R01 DK104176 (PI: Fang / Tseng) 8/20/2015 - 7/31/2020
 Role: Biostatistician
 A biobehavioral model of diabetes risk in Chinese immigrants
16. NIH R21 CA198036 (PI: Wen) 9/1/2016 - 8/31/2019
 Role: Biostatistician
 Preventing postpartum smoking relapse: a Twitter-enabled supportive intervention
17. NIH R01 CA204271 (PI: Heckman) 12/1/2016 - 2/15/2019
 Role: Biostatistician
 Modifying young adult skin cancer risk and protective behaviors (UV4.me2): A hybrid type 2
 dissemination/effectiveness trial
18. AHRQ HS019001 (PI: Wen) 8/1/2011 - 7/31/2016
 AHRQ Role: Biostatistician
 MyHealthPortal: Using an electronic portal to empower patients with breast cancer

FOUNDATION AND INDUSTRY FUNDING HISTORY

1. HealthWell Foundation 4864-4904-2693 (PI: Miller) 1/1/2022 - 9/31/2022
 Role: Biostatistician
 Burdens, Experience and Perspectives of Co-Pay Assistance Foundation Grant Recipients (MPI)
2. ACS RWIA-21-122-01-RWIA (PI: Lynch) 1/1/2022 - 12/31/2022
 Role: Biostatistician
 Investigating Disparities in Metastatic Pancreatic Cancer: Effect of Treatment Type and Therapeutic
 Delays on Survival
3. Prevent Cancer Foundation (PI: Miller) 1/15/2022 - 6/15/2023
 Role: Biostatistician
 Feasibility of Text Messaging to Reduce Urban Cervical Cancer Disparities

4. ACS RSG-20-029-01-CPPB (PI: Reese) 9/1/2020 - 6/15/2023
 Role: Biostatistician
 Sexual QOL Intervention for Couples Facing Metastatic Breast Cancer
5. ACS MRSG-18-098-01-CPHPS (PI: Lynch) 7/1/2018 - 6/15/2023
 Role: Biostatistician
 Multilevel, precision-based approach to address prostate cancer disparities
6. NCCN/Eli Lilly (PI: Dotan) 12/17/2019 - 6/15/2023
 Role: Biostatistician
 Improving the approach to and management of the older patient with metastatic gastric cancer
7. Pfizer W1206759 (PI: Heckman) 2/24/2016 - 2/15/2019
 Role: Biostatistician
 ITCH-RELIEF: Interactive toolbox of comprehensive health resources to enhance living with itch - educational facilitation (for adults)
8. NCCN/Pfizer 22862401 (PI: Dotan) 1/1/2016 - 12/31/2019
 Role: Biostatistician Improving the approach to and management of the older metastatic breast cancer patient via a provider didactic intervention

INVITED TALKS, PARTICIPATION IN CONFERENCES

1. **Handorf E**, Geynisman D, Beck JR. Optimizing multivariate calibration parameters in microsimulation models. Society for Medical Decision Making (SMDM), Seattle, Washington, 2022. (Selected oral presentation)
2. **Handorf E**, Correa A, Ramamurthy C, Geynisman D, Beck JR. Cost-effectiveness analysis of therapy sequence in metastatic prostate cancer: Generic availability of targeted hormonal therapy. Poster presentation. Society for Medical Decision Making (SMDM), Seattle, Washington, 2022.
3. **Handorf E**, Correa A, Ramamurthy C, Geynisman D, Beck RJ. Cost effectiveness analysis of multiple lines of cancer therapy. Vanderbilt University, Department of Biostatistics, December 2021. (Invited)
4. **Handorf E**, Smaldone MC, Movva S, Mitra N. Propensity score weighting approaches for analysis of survival data with non-proportional hazards. Oral presentation. Eastern North American Region (ENAR) of the International Biometrics Society, (virtual) 2021. (Invited)
5. **Handorf E**, Yin Y, Slifker M, Lynch S. Machine Learning Approaches for Identifying Social-Environmental Variables Predictive of Health Outcomes. Poster presentation, Joint Statistical Meeting, Philadelphia, PA (virtual), 2020.
6. **Handorf E**, Smaldone MC, Movva S, Mitra N. Propensity score weighting approaches for analysis of survival data with non-proportional hazards. Jefferson University, Division of Biostatistics, Philadelphia, PA, 2019. (Invited)
7. **Handorf E**, Correa A, Ramamurthy C, Geynisman D, Beck JR. Microsimulations for cost-effectiveness analysis: Modelling therapy sequence in advanced cancer. Oral presentation, Eastern North American Region (ENAR) of the International Biometrics Society, Philadelphia, PA, 2019. (Invited)
8. **Handorf E**, Smaldone MC, Movva S, Mitra N. Propensity score weighting approaches for analysis of survival data with non-proportional hazards. Drexel University, Department of Epidemiology and Biostatistics, Philadelphia, PA, 2018. (Invited)
9. **Handorf E**, Correa A, Ramamurthy C, Geynisman D, JR Beck. Cost-effectiveness analysis of therapy sequence in advanced prostate cancer: A microsimulation. Society for Medical Decision Making (SMDM), Montreal, Quebec, Canada, 2018. (Selected oral presentation)

10. **Handorf E** and Lynch S. Challenges in analyzing socioeconomic, population-based “Big Data”: A U.S. Census and cancer registry example. Oral presentation, Philadelphia Big Data Symposium, Philadelphia, PA, 2017.
11. **Handorf E**, Darlow S, Slifker M, Heckman C, Ritterband L. Evaluating quality of web panel survey data via clustering and latent classes. Poster presentation, Eastern North American Region (ENAR) of the International Biometrics Society, Austin, TX, 2016.
12. Mitra N, **Handorf E**, Kanetsky P. and Kawut S. Assessing the sensitivity of genetic associations to unmeasured confounding under a causal framework. Oral presentation, Eastern North American Region (ENAR) of the International Biometrics Society, Baltimore, MD, 2014. (Invited)
13. **Handorf E**, Ross E. Uncertainty in pilot parameter estimates: A comparison of methods to size full trials. Poster presentation, Joint Statistical Meeting, Montreal, Quebec, Canada, 2013.
14. **Handorf E**, Bekelman J, Heitjan D, and Mitra N. A general framework for sensitivity analysis of cost data with unmeasured confounding. Poster presentation, Eastern North American Region (ENAR) of the International Biometrics Society, Orlando, FL, 2013.
15. **Handorf E**, Bekelman J, Heitjan D, and Mitra N. Assessing the sensitivity of net monetary benefits using non-linear models. Poster presentation, International Conference in Health Policy Statistics, Cleveland, OH, 2011.
16. **Handorf E**, Bekelman J, Heitjan D, and Mitra N. A sensitivity analysis for the treatment effect on cost with unmeasured confounding. Contributed talk, Eastern North American Region (ENAR) of the International Biometrics Society, Miami, FL, 2011. 1.
17. **Handorf E**, Bristol-Demeter M, Chen J, Domchek S, and Armstrong K. Improving risk stratification for mammography results by incorporating genetic and standard risk factors. Poster presentation, National Conference on Genomics and Public Health, Bethesda, MD, 2010.

PEER-REVIEWED PUBLICATIONS

Available online: www.ncbi.nlm.nih.gov/myncbi/1HUDhywNJ6-Qq/bibliography/public/

Statistical Methods and Applications

1. **Handorf EA**, Smaldone M, Movva S, Mitra N. Analysis of survival data with non-proportional hazards: A comparison of propensity score weighted methods. *Biometrical Journal* (In press). Preprint: <https://arxiv.org/abs/2009.00785>
2. **Handorf E**, Yin Y, Slifker M, Lynch S. Variable selection in social-environmental data: Sparse regression and tree ensemble machine learning approaches. *BMC Medical Research Methodology*. 2020 Dec 10;20(1):302. Preprint: <https://arxiv.org/abs/2009.00065>
3. **Handorf EA**, Heitjan DF, Bekelman JE, Mitra N. Estimating cost-effectiveness from claims and registry data with measured and unmeasured confounders. *Statistical Methods in Medical Research*. 2018;28(7):2227-42.
4. **Handorf EA**, Heckman CJ, Darlow S, Slifker M, Ritterband L. A hierarchical clustering approach to identify repeated enrollments in web survey data. *PLOS One*. 2018;13(9):e0204394.
5. Li J, **Handorf E**, Bekelman J, Mitra N. Propensity score and doubly robust methods for estimating the effect of treatment on censored cost. *Statistics in Medicine*. 2016;35(12):1985-99
6. **Handorf EA**, Bekelman JE, Heitjan DF, Mitra N. Evaluating costs with unmeasured confounding: a sensitivity analysis for the treatment effect. *The Annals of Applied Statistics*. 2013;7(4):2062-80.

Observational studies of treatment effects and risk factors

7. Zarrabi KK, **Handorf E**, Miron B, Zibelman MR, Anari F, Ghatalia P, Plimack ER, Geynisman DM. Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma. *The Oncologist*. 2023 Feb 8;28(2):157-164.
8. Miron B, **Handorf E**, Zarrabi K, Zibelman MR, Anari F, Ghatalia P, Plimack ER, Geynisman DM. Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors. *Urologic Oncology*. 2022 Oct;40(10):454.e9-454.e16.
9. Bodor JN, Bauman JR, **Handorf EA**, Ross EA, Clapper ML, Treat J. Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy. *Journal of Cancer Research and Clinical Oncology*. 2023 May;149(5):1755-1763.
10. Ghatalia P, **Handorf EA**, Geynisman DM, Deng M, Zibelman MR, Abbosh P, Anari F, Greenberg RE, Viterbo R, Chen D, Smaldone MC, Kutikov A, Uzzo RG. The role of cytoreductive nephrectomy in metastatic renal cell carcinoma: A real-world multi-institutional analysis. *Journal of Urology*. 2022 Jul;208(1):71-79.
11. Martin JM, **Handorf EA**, Montero AJ, Goldstein LJ. Systemic therapies following progression on first-line CDK4/6-inhibitor treatment: Analysis of real-world data. *The Oncologist*. 2022 Jun 8;27(6):441-446
12. Barrak D, Villano AM, Villafane-Ferriol N, Stockton LG, Hill MV, Deng M, **Handorf EA**, Reddy SS. Total neoadjuvant therapy for pancreatic adenocarcinoma increases probability for a complete pathologic response. *European Journal of Surgical Oncology*. 2022 Jun;48(6):1356-1361.
13. Ginsburg KB, Chandra AA, **Handorf EA**, Schober JP, Mahmoud A, Smaldone MC, Viterbo R, Uzzo RG, Greenberg RE, Chen DYT, Kutikov A, Correa AF. Association of surgical approach With treatment burden, oncological effectiveness, and perioperative morbidity in adrenocortical carcinoma. *Clinical Genitourinary Cancer*. 2022 Oct;20(5):497.e1-497.e7.
14. Winer A, **Handorf E**, Dotan E. Dosing schedules of gemcitabine and nab-paclitaxel for older adults With metastatic pancreatic cancer. *JNCI Cancer Spectrum*. 2021 Aug 23;5(5):pkab074. doi: 10.1093/jncics/pkab074.
15. Ginsburg KB, Chandra AA, Schober JP, **Handorf EA**, Uzzo RG, Greenberg RE, Chen DY, Viterbo R, Smaldone MC, Kutikov A, Hallman MA, Correa AF. Identification of oncological characteristics associated with improved overall survival in patients with adrenocortical carcinoma treated with adjuvant radiation therapy: Insights from the National Cancer Database. *Urologic Oncology*. 2021 Nov;39(11):791.e1-791.e7. doi: 10.1016/j.urolonc.2021.06.019.
16. Burbure N, **Handorf E**, Ridge JA, Bauman J, Liu JC, Giri A, Galloway TJ. Prognostic significance of human papillomavirus status and treatment modality in hypopharyngeal cancer. *Head & Neck*. 2021 Oct;43(10):3042-3052.
17. Zhang E, Wang L, Shaikh T, **Handorf E**, Wong JK, Hoffman JP, Reddy S, Cooper HS, Cohen SJ, Dotan E, Meyer JE. Neoadjuvant chemoradiation impacts the prognostic effect of surgical margin status in pancreatic adenocarcinoma. *Annals of Surgical Oncology*. 2022 Jan;29(1):354-363.
18. Moslim MA, **Handorf E**, Reddy SS, Greco SH, Farma JM. Partial Gastrectomy is associated with improved overall survival in signet-ring cell gastric cancer. *Journal of Surgical Research*. 2021 Oct;266:27-34.
19. Moslim MA, Minarich MJ, Deng M, **Handorf E**, Greco SH, Reddy SS, Farma JM. Treatment at an academic cancer center confers better survival by stage for signet-ring cell and non-signet-ring cell gastric cancer. *Annals of Surgical Oncology*. 2021 Aug;28(8):4423-4432.

20. Joshi SS, **Handorf E**, Sienko D, Zibelman M, Uzzo RG, Kutikov A, Horwitz EM, Smaldone MC, Geynisman DM. Treatment facility volume and survival in patients with advanced prostate cancer. *European Urology Oncology*. 2020;3(1):104-111
21. Ward WH, DeMora L, **Handorf E**, Sigurdson ER, Ross EA, Daly JM, Aggon AA, Bleicher RJ. Preoperative delays in the treatment of DCIS and the associated incidence of invasive breast cancer. *Annals of Surgical Oncology*. 2020 Feb;27(2):386-396.
22. Mateo AM, Mazor AM, Obeid E, Daly JM, Sigurdson ER, **Handorf EA**, DeMora L, Aggon AA, Bleicher RJ. Time to surgery and the impact of delay in the non-neoadjuvant setting on triple-negative breast cancers and other phenotypes. *Annals of Surgical Oncology*. 2019 Nov 11.
23. Patel D, **Handorf E**, von Mehren M, Martin L, Movva S. Adjuvant chemotherapy in uterine leiomyosarcoma: Trends and factors impacting usage. *Sarcoma*. 2019;2019:3561501.
24. Mazor AM, Mateo AM, Demora L, Sigurdson ER, **Handorf E**, Daly JM, Aggon AA, Anderson PR, Weiss SE, Bleicher RJ. Breast conservation versus mastectomy in patients with T3 breast cancers (> 5 cm): an analysis of 37,268 patients from the National Cancer Database. *Breast Cancer Research and Treatment*. 2019;173(2):301-11.
25. Mateo AM, Mazor AM, DeMora L, Sigurdson ER, **Handorf EA**, Daly JM, Aggon AA, Obeid E, Hayes SB, Bleicher RJ. Patterns of care and efficacy of chemotherapy and radiotherapy in skin-involved breast cancers of all sizes. *Clinical Breast Cancer*. 2019.
26. Gerson JN, **Handorf E**, Villa D, Gerrie AS, Chapani P, Li S, Medeiros LJ, Wang MI, Cohen JB, Calzada O, Churnetski MC, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose JM, Bast MA, Fenske TS, Narayana Rao Gari S, Maddocks KJ, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns TF, Donovan AM, Wagner-Johnston N, Messmer M, Mehta A, Anderson JK, Reddy N, Kovach AE, Landsburg DJ, Glenn M, Inwards DJ, Karmali R, Kaplan JB, Caimi PF, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual JE, Lue JK, Diefenbach C, Fisher RI, Barta SK. Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era. *Journal of Clinical Oncology*. 2019;37(6):471-80.
27. Avkshtol V, **Handorf EA**, Ridge JA, Leachman BK, Liu JC, Bauman J, Galloway TJ. Examining adjuvant radiation dose in head and neck squamous cell carcinoma. *Head & Neck*. 2019;41(7):2133-2142.
28. Ristau BT, **Handorf EA**, Cahn DB, Kutikov A, Uzzo RG, Smaldone MC. Partial nephrectomy is not associated with an overall survival advantage over radical nephrectomy in elderly patients with stage Ib-II renal masses: An analysis of the National Cancer Database. *Cancer*. 2018;124(19):3839-48.
29. Joshi SS, **Handorf EA**, Zibelman M, Plimack ER, Uzzo RG, Kutikov A, Smaldone MC, Geynisman DM. Treatment facility volume and survival in patients with metastatic renal cell carcinoma: A registry-based analysis. *European Urology*. 2018;74(3):387-93.
30. Correa AF, **Handorf E**, Joshi SS, Geynisman DM, Kutikov A, Chen DY, Uzzo RG, Viterbo R, Greenberg RE, Smaldone MC. Differences in survival associated with performance of lymph node dissection in patients with invasive penile cancer: results from the National Cancer Database. *The Journal of Urology*. 2018;199(5):1238-44.
31. Cahn DB, **Handorf EA**, Ghiraldi EM, Ristau BT, Geynisman DM, Churilla TM, Horwitz EM, Sobczak ML, Chen DYT, Viterbo R, Greenberg RE, Kutikov A, Uzzo RG, Smaldone MC. Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer. *Cancer*. 2017;123(22):4337-45.
32. Shaikh T, **Handorf EA**, Murphy CT, Mehra R, Ridge JA, Galloway TJ. The impact of radiation treatment time on survival in patients with head and neck cancer. *International Journal of Radiation Oncology, Biology, Physics*. 2016;96(5):967-75.

33. Murphy CT, Galloway TJ, **Handorf EA**, Egleston BL, Wang LS, Mehra R, Flieder DB, Ridge JA. Survival impact of increasing time to treatment initiation for patients with head and neck cancer in the United States. *Journal of Clinical Oncology*. 2016;34(2):169-78.
34. Geynisman DM, **Handorf E**, Wong YN, Doyle J, Plimack ER, Horwitz EM, Canter DJ, Uzzo RG, Kutikov A, Smaldone MC. Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma. *Cancer Medicine*. 2016;5(2):192-9.
35. Movva S, von Mehren M, Ross EA, **Handorf E**. Patterns of chemotherapy administration in high-risk soft tissue sarcoma and impact on overall survival. *Journal of the National Comprehensive Cancer Network*. 2015;13(11):1366-74.
36. Bekelman JE, Mitra N, **Handorf EA**, Uzzo RG, Hahn SA, Polsky D, Armstrong K. Effectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate cancer. *Journal of Clinical Oncology*. 2015;33(7):716-22.
37. Johnson ME, **Handorf EA**, Martin JM, Hayes SB. Postmastectomy radiation therapy for T3N0: a SEER analysis. *Cancer*. 2014;120(22):3569-74.
38. Bekelman JE, **Handorf EA**, Guzzo T, Evan Pollack C, Christodouleas J, Resnick MJ, Swisher-McClure S, Vaughn D, Ten Have T, Polsky D, Mitra N. Radical cystectomy versus bladder-preserving therapy for muscle-invasive urothelial carcinoma: examining confounding and misclassification bias in cancer observational comparative effectiveness research. *Value in Health*. 2013;16(4):610-8.

Cost and cost-effectiveness studies

39. Srivastava A, Uzzo RN, Lee J, Cho E, Grieco A, Masic S, **Handorf E**, Chen DYT, Viterbo R, Greenberg RE, Smaldone MC, Kutikov A, Uzzo RG. Renal mass biopsy: A strategy to reduce associated costs and morbidity when managing localized renal masses. *Urologic Oncology*. 2021 Nov;39(11):790.e9-790.e15.
40. Ramamurthy C*, **Handorf EA***, Correa AF, Beck JR, Geynisman DM. Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naive prostate cancer. *Urologic Oncology*. 2019;37(10):688-95. (*Co-first author)
41. Geynisman DM, Meeker CR, Doyle JL, **Handorf EA**, Bilusic M, Plimack ER, Wong YN. Provider and patient burdens of obtaining oral anticancer medications. *The American Journal of Managed Care*. 2018;24(4):e128-e33.
42. Smith A, **Handorf E**, Arjmand E, Lango MN. Predictors of regional Medicare expenditures for otolaryngology physician services. *The Laryngoscope*. 2017;127(6):1312-7.
43. **Handorf EA**, McElligott S, Vachani A, Langer CJ, Bristol Demeter M, Armstrong K, Asch DA. Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung. *Journal of Oncology Practice*. 2012;8(5):267-74.

Prospective Trials

44. Ma GX, Zhu L, Lu W, **Handorf E**, Tan Y, Yeh MC, Johnson C, Guerrier G, Nguyen MT. Improving Long-Term Adherence to Monitoring/Treatment in Underserved Asian Americans with Chronic Hepatitis B (CHB) through a Multicomponent Culturally Tailored Intervention: A Randomized Controlled Trial. *Healthcare (Basel)*. 2022 Oct 5;10(10):1944. doi: 10.3390/healthcare10101944. PMID: 36292391; PMCID: PMC9601489. Format:
45. Reese JB, Bober SL, Sorice KA, **Handorf E**, Chu CS, Middleton D, McIlhenny S, El-Jawahri A. Starting the Conversation: randomized pilot trial of an intervention to promote effective clinical communication about sexual health for gynecologic cancer survivors. *J Cancer Surviv*. 2023 Jan 6. doi: 10.1007/s11764-022-01327-4. (In press)

46. Reese JB, El-Jawahri A, Sorice K, Cruz C, Bober SL, Daly MB, Zimmaro LA, Beach MC, Wittenberg E, Wolff AC, **Handorf E**, Lepore SJ. Investigating the impact of the COVID-19 pandemic on breast cancer clinicians' communication about sexual health. *Supportive Care in Cancer*. 2022 Jul;30(7):5801-5810.
47. Marziliano A, Diefenbach MA, Hudson SV, Tagai EK, **Handorf EA**, Bator A, Miller SM. Demographic and psychosocial characteristics associated with use of a prostate cancer survivorship website: Implications From a multisite randomized controlled trial. *Journal of Medical Internet Research*. 2022 Mar 21;24(3):e27890.
48. Zimmaro LA, Sorice KA, **Handorf EA**, Daly MB, Reese JB. Understanding clinical communication about mood disturbance symptoms among breast cancer patients: A mixed methods analysis. *Patient Education and Counseling*. 2022 Jul;105(7):2089-2095.
49. Zimmaro LA, Moss A, Reibel DK, **Handorf EA**, Reese JB, Fang CY. A telephone-adapted mindfulness-based stress reduction program: Preliminary effects among healthcare employees. *Behavioral science (Basel)*. 2021 Oct 18;11(10):139.
50. Tagai EK, Miller SM, Hudson SV, Diefenbach MA, **Handorf E**, Bator A, Marziliano A, Kutikov A, Hall SJ, Vira M, Schwartz M, Kim IY, Kim S. Improved cancer coping from a web-based intervention for prostate cancer survivors: A randomized controlled trial. *Psychooncology*. 2021 Sep;30(9):1466-1475.
51. Reese JB, Sorice KA, Pollard W, **Handorf E**, Beach MC, Daly MB, Porter LS, Tulsy JA, Lepore SJ. Efficacy of a multimedia intervention in facilitating breast cancer patients' clinical communication about sexual health: Results of a randomized controlled trial. *Psychooncology*. 2021 May;30(5):681-690.
52. Ward WH, Meeker CR, **Handorf E**, Hill MV, Einarson M, Alpaugh RK, Holden TL, Astsaturov I, Denlinger CS, Hall MJ, Reddy SS, Sigurdson ER, Dotan E, Zibelman M, Meyer JE, Farma JM, Vijayvergia N. Feasibility of fitness tracker usage to assess activity level and toxicities in patients With colorectal cancer. *JCO Clinical Cancer Informatics*. 2021 Jan;5:125-133.
53. Reese JB, Zimmaro LA, Bober SL, Sorice K, **Handorf E**, Wittenberg E, El-Jawahri A, Beach MC, Wolff AC, Daly MB, Izquierdo B, Lepore SJ. Mobile technology-based (mLearning) intervention to enhance breast cancer clinicians' communication about sexual health: A pilot trial. *Journal of the National Comprehensive Cancer Network*. 2021 Aug 13;19(10):1133-1140.
54. Reese JB, Zimmaro LA, Lepore SJ, Sorice KA, **Handorf E**, Daly MB, Schover LR, Kashy D, Westbrook K, Porter LS. Evaluating a couple-based intervention addressing sexual concerns for breast cancer survivors: study protocol for a randomized controlled trial. *Trials*. 2020 Feb 12;21(1):173.
55. Reese JB, Smith KC, **Handorf E**, Sorice K, Bober SL, Bantug ET, Schwartz S, Porter LS. A randomized pilot trial of a couple-based intervention addressing sexual concerns for breast cancer survivors. *Journal of Psychosocial Oncology*. 2019;37(2):242-63.
56. Reese JB, Lepore SJ, Daly MB, **Handorf E**, Sorice KA, Porter LS, Tulsy JA, Beach MC. A brief intervention to enhance breast cancer clinicians' communication about sexual health: Feasibility, acceptability, and preliminary outcomes. *Psycho-oncology*. 2019;28(4):872-9.
57. Heckman CJ, Auerbach MV, Darlow S, **Handorf EA**, Raivitch S, Manne SL. Association of skin cancer risk and protective behaviors with health literacy among young adults in the USA. *International Journal of Behavioral Medicine*. 2019;26(4):372-9.
58. Churilla TM, Chowdhury IH, **Handorf E**, Collette L, Collette S, Dong Y, Alexander BM, Kocher M, Soffietti R, Claus EB, Weiss SE. Comparison of local control of brain metastases with stereotactic radiosurgery vs surgical resection: A secondary analysis of a randomized clinical trial. *JAMA Oncology*. 2019;5(2):243-247.
59. Heckman CJ, **Handorf E**, Auerbach MV. Prevalence and correlates of skin cancer screening among indoor tanners and nontanners. *JAMA Dermatology*. 2018;154(5):554-60.

60. Shaikh T, Li T, **Handorf EA**, Johnson ME, Wang LS, Hallman MA, Greenberg RE, Price RA, Jr., Uzzo RG, Ma C, Chen D, Geynisman DM, Pollack A, Horwitz EM. Long-term patient-reported outcomes from a phase 3 randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. *International Journal of Radiation Oncology, Biology, Physics*. 2017;97(4):722-31.
61. Heckman CJ, **Handorf EA**, Darlow SD, Ritterband LM, Manne SL. An online skin cancer risk-reduction intervention for young adults: Mechanisms of effects. *Health Psychology*. 2017;36(3):215-25.
62. Heckman CJ, **Handorf E**, Darlow SD, Yaroch AL, Raivitch S. Refinement of measures to assess psychosocial constructs associated with skin cancer risk and protective behaviors of young adults. *Journal of Behavioral Medicine*. 2017;40(4):574-82.
63. Fang CY, Ma GX, **Handorf EA**, Feng Z, Tan Y, Rhee J, Miller SM, Kim C, Koh HS. Addressing multilevel barriers to cervical cancer screening in Korean American women: A randomized trial of a community-based intervention. *Cancer*. 2017;123(6):1018-26.
64. Churilla TM, **Handorf E**, Collette S, Collette L, Dong Y, Aizer AA, Kocher M, Soffiatti R, Alexander BM, Weiss SE. Whole brain radiotherapy after stereotactic radiosurgery or surgical resection among patients with one to three brain metastases and favorable prognoses: a secondary analysis of EORTC 22952-26001. *Annals of Oncology*. 2017;28(10):2588-94.
65. Heckman CJ, Darlow SD, Ritterband LM, **Handorf EA**, Manne SL. Efficacy of an intervention to alter skin cancer risk behaviors in young adults. *American Journal of Preventive Medicine*. 2016;51(1):1-11.
66. Hall MJ, Herda MM, **Handorf EA**, Rybak CC, Keleher CA, Siemon M, Daly MB. Direct-to-patient disclosure of results of mismatch repair screening for Lynch syndrome via electronic personal health record: a feasibility study. *Genetics in Medicine*. 2014;16(11):854-61

Health disparities research

67. Bernstein AN, Talwar R, **Handorf E**, Syed K, Danella J, Ginzburg S, Belkoff L, Reese AC, Tomaszewski J, Trabulsi E, Singer EA, Jacobs B, Kutikov A, Uzzo R, Raman JD, Guzzo T, Smaldone MC, Correa A. Assessment of prostate cancer treatment among black and white patients during the COVID-19 pandemic. *JAMA Oncology*. 2021 Oct 1;7(10):1467-1473.
68. Mayhand KN, **Handorf EA**, Ortiz AG, Gonzalez ET, Devlin A, Sorice KA, Esnaola N, Fisher S, Lynch SM. Effect of neighborhood and individual-level socioeconomic factors on colorectal cancer screening adherence. *International Journal of Environmental Research and Public Health*. 2021 Apr 21;18(9):4398.
69. Madnick D, **Handorf E**, Ortiz A, Sorice K, Nagappan L, Moccia M, Cheema K, Vijayvergia N, Dotan E, Lynch SM. Investigating disparities: the effect of social environment on pancreatic cancer survival in metastatic patients. *Journal of Gastrointestinal Oncology*. 2020 Aug;11(4):633-643.
70. Lynch SM, **Handorf E**, Sorice KA, Blackman E, Bealin L, Giri VN, Obeid E, Ragin C, Daly M. The effect of neighborhood social environment on prostate cancer development in black and white men at high risk for prostate cancer. *PLoS One*. 2020 Aug 13;15(8):e0237332.
71. Lynch SM, Sorice K, Tagai EK, **Handorf EA**. Use of empiric methods to inform prostate cancer health disparities: Comparison of neighborhood-wide association study "hits" in black and white men. *Cancer*. 2020 Jan 1;126(9):1949-1957.
72. Parker DC, **Handorf E**, Smaldone MC, Uzzo RG, Pitt H, Reese AC. Race and postoperative complications following urologic cancer surgery: An ACS-NSQIP analysis. *Urologic Oncology*. 2017;35(12):670.e1-e6.

Treatment patterns and quality

73. Iyer P, Deng M, **Handorf EA**, Nakhoda S, Dotan E. Assessing Oncologists' Adoption of Biomarker Testing in Metastatic Colorectal Cancer Using Real World Data. *JNCI Cancer Spectrum*. 2022 Nov 1;6(6):pkac065.

74. Seedor RS, Meeker CR, Lewis B, **Handorf EA**, Filchner KA, Varadarajan R, Hensold J, Padmanabhan A, Negin B, Blankstein K, Chawla NR, Song WF, Epstein J, Winn J, Goldstein LJ, Dotan E. Prospective comparison of geriatric assessment and provider's assessment of older adults with metastatic breast cancer in the community. *The Oncologist*. 2022 Mar 4;27(2):e133-e141.
75. Hill MV, Vidri RJ, Deng M, **Handorf E**, Olszanski AJ, Farma JM. Real-world frequency of BRAF testing and utilization of therapies in patients with advanced melanoma. *Melanoma Research*. 2022 Apr 1;32(2):79-87.
76. Moslim MA, Deng M, **Handorf E**, Greco SH, Farma JM. Optimal care and survival for signet-ring cell and non-signet-ring cell gastric cancer are more achievable at academic cancer centers. *American Journal of Surgery*. 2021 Nov;222(5):969-975.
77. Moten AS, von Mehren M, Reddy S, Howell K, **Handorf E**, Farma JM. Treatment patterns and distance to treatment facility for soft tissue sarcoma of the extremity. *Journal of Surgical Research*. 2020 Aug 13;256:492-501.
78. Ebersole B, Lango M, Ridge J, **Handorf E**, Farma J, Clark S, Jamal N. Dysphagia screening for pneumonia prevention in a cancer hospital: results of a quality/safety initiative. *Otolaryngology-Head and Neck Surgery*. 2020 Feb;162(2):220-229.
79. Shaikh T, **Handorf EA**, Meyer JE, Hall MJ, Esnaola NF. Mismatch repair deficiency Testing in patients with colorectal cancer and nonadherence to testing guidelines in young adults. *JAMA Oncology*. 2018;4(2):e173580.
80. Esposito AC, Crawford J, Sigurdson ER, **Handorf EA**, Hayes SB, Boraas M, Bleicher RJ. Omission of radiotherapy after breast conservation surgery in the postneoadjuvant setting. *The Journal of Surgical Research*. 2018;221:49-57.
81. Joshi SS, **Handorf E**, Strauss D, Correa AF, Kutikov A, Chen DYT, Viterbo R, Greenberg RE, Uzzo RG, Smaldone MC, Geynisman DM. Treatment trends and outcomes for patients with lymph node-positive cancer of the penis. *JAMA Oncology*. 2018;4(5):643-9.
82. Churilla TM, DeMora L, **Handorf E**, Zaorsky NG, Dong Y, Denlinger CS, Sigurdson ER, Meyer JE. Deviations from standard chemoradiation among early-stage anal cancer patients. *International Journal of Radiation Oncology, Biology, Physics*. 2018;100(4):945-9.
83. Smaldone MC, Egleston B, Hollingsworth JM, Hollenbeck BK, Miller DC, Morgan TM, Kim SP, Malhotra A, **Handorf E**, Wong YN, Uzzo RG, Kutikov A. Understanding treatment disconnect and mortality trends in renal cell carcinoma using tumor registry data. *Medical Care*. 2017;55(4):398-404.
84. Cahn DB, **Handorf E**, Ristau BT, Geynisman DM, Simhan J, Kutikov A, Greenberg RE, Viterbo R, Chen DYT, Uzzo RG, Smaldone MC. Contemporary practice patterns and survival outcomes for locally advanced urethral malignancies: A National Cancer Database Analysis. *Urol Oncol*. 2017 Dec;35(12):670.e15-670.e21.
85. Reddy SS, **Handorf B**, Farma JM, Sigurdson ER. Trends with neoadjuvant radiotherapy and clinical staging for those with rectal malignancies. *World Journal of Gastrointestinal Surgery*. 2017;9(4):97-102.
86. Lango MN, **Handorf E**, Arjmand E. The geographic distribution of the otolaryngology workforce in the United States. *The Laryngoscope*. 2017;127(1):95-101.
87. Cripe J, **Handorf E**, Brown J, Jain A, Rubin S, Mantia-Smaldone G. National Cancer Database Report of lymphadenectomy trends in endometrial cancer. *International Journal of Gynecological Cancer*. 2017;27(7):1408-15.

88. Smaldone MC, **Handorf E**, Kim SP, Thompson RH, Costello BA, Corcoran AT, Wong YN, Uzzo RG, Leibovich BC, Kutikov A, Boorjian SA. Temporal trends and factors associated with systemic therapy after cytoreductive nephrectomy: an analysis of the National Cancer Database. *The Journal of Urology*. 2015;193(4):1108-13.
89. Shaikh T, **Handorf EA**, Murphy CT, Kutikov A, Uzzo RG, Hallman M, Horwitz EM, Smaldone MC. Contemporary trends in the utilization of radiotherapy in patients with renal cell carcinoma. *Urology*. 2015;86(6):1165-73.
90. Murphy CT, Galloway TJ, **Handorf EA**, Wang L, Mehra R, Flieder DB, Ridge JA. Increasing time to treatment initiation for head and neck cancer: an analysis of the National Cancer Database. *Cancer*. 2015;121(8):1204-13.
91. Corcoran AT, **Handorf E**, Canter D, Tomaszewski JJ, Bekelman JE, Kim SP, Uzzo RG, Kutikov A, Smaldone MC. Variation in performance of candidate surgical quality measures for muscle-invasive bladder cancer by hospital type. *BJU International*. 2015;115(2):230-7.
92. Tomaszewski JJ, **Handorf E**, Corcoran AT, Wong YN, Mehrazin R, Bekelman JE, Canter D, Kutikov A, Chen DY, Uzzo RG, Smaldone MC. Care transitions between hospitals are associated with treatment delay for patients with muscle invasive bladder cancer. *The Journal of Urology*. 2014;192(5):1349-54.
93. Martin JM, **Handorf EA**, Kutikov A, Uzzo RG, Bekelman JE, Horwitz EM, Smaldone MC. The rise and fall of prostate brachytherapy: use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base. *Cancer*. 2014;120(14):2114-21.

Non-interventional behavioral and psychosocial studies

94. Somayaji KH, **Handorf E**, Meeker CR, Lewis B, Filchner K, Goldstein LJ, Dotan E. Psychosocial needs of older patients with metastatic breast cancer treated at community centers. *J Geriatr Oncol*. 2023 Mar;14(2):101444.
95. Ma GX, Zhu L, Lu W, Tan Y, Truehart J, Johnson C, **Handorf E**, Nguyen MT, Yeh MC, Wang MQ. Examining the influencing factors of chronic hepatitis B monitoring behaviors among Asian Americans: Application of the information-motivation-behavioral model. *International Journal of Environmental Research and Public Health*. 2022 Apr 12;19(8):4642.
96. Bhimla A, Zhu L, Lu W, Golub S, Enemchukwu C, **Handorf E**, Tan Y, Yeh MC, Nguyen MT, Wang MQ, Ma GX. Factors associated with hepatitis B medication adherence and persistence among underserved Chinese and Vietnamese Americans. *Journal of Clinical Medicine*. 2022 Feb 7;11(3):870.
97. Tseng M, Walton E, **Handorf E**, Fang CY. Ethnic density, social support, and loneliness among Chinese immigrants in Philadelphia. *Wellbeing, Space, and Society*. 2021;2:100050.
98. Hunt A, **Handorf E**, Blau M, Chertock Y, Fang C, Hall MJ, Jain R. Psychological distress in patients with metastatic cancer enrolling on phase I clinical trials. *Journal of Cancer Survivorship*. 2021 Jun;15(3):398-402.
99. Zimmaro LA, Deng M, **Handorf E**, Fang CY, Denlinger CS, Reese JB. Understanding benefit finding among patients with colorectal cancer: a longitudinal study. *Supportive Care in Cancer*. 2021 May;29(5):2355-2362.
100. Fang CY, **Handorf EA**, Rao AD, Siu PT, Tseng M. Acculturative Stress and depressive symptoms among Chinese immigrants: The role of gender and social support. *Journal of Racial and Ethnic Health Disparities*. 2021 Oct;8(5):1130-1138.
101. Reese JB, Sorice KA, Pollard W, Zimmaro LA, Beach MC, **Handorf E**, Lepore SJ. Understanding sexual help-seeking for women with breast cancer: What distinguishes women who seek help from those who do not? *Journal of Sexual Medicine*. 2020 Sep;17(9):1729-1739.

102. Reese JB, **Handorf E**, Haythornthwaite JA. Sexual quality of life, body image distress, and psychosocial outcomes in colorectal cancer: a longitudinal study. *Supportive Care in Cancer*. 2018;26(10):3431-40.
103. Reese JB, Lepore SJ, **Handorf EA**, Haythornthwaite JA. Emotional approach coping and depressive symptoms in colorectal cancer patients: The role of the intimate relationship. *Journal of Psychosocial Oncology*. 2017;35(5):578-96.
104. Longacre ML, Valdmanis VG, **Handorf EA**, Fang CY. Work impact and emotional stress among informal caregivers for older adults. *The Journals of Gerontology Series B, Psychological Sciences and Social Sciences*. 2017;72(3):522-31.

Basic and Translational Science

105. Gabitova-Cornell L, Surumbayeva A, Peri S, Franco-Barraza J, Restifo D, Weitz N, Ogier C, Goldman AR, Hartman TR, Francescone R, Tan Y, Nicolas E, Shah N, **Handorf EA**, Cai KQ, O'Reilly AM, Sloma I, Chiaverelli R, Moffitt RA, Khazak V, Fang CY, Golemis EA, Cukierman E, Astsaturov I. Cholesterol pathway inhibition induces TGF- β signaling to promote basal differentiation in pancreatic cancer. *Cancer Cell*. 2020 Oct 12;38(4):567-583.e11.
106. Wang Y, Bernhardt AJ, Nacson J, Kraus JJ, Tan YF, Nicolas E, Radke MR, **Handorf E**, Llop-Guevara A, Balmaña J, Swisher EM, Serra V, Peri S, Johnson N. BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance. *Nature Communications*. 2019 Dec 11;10(1):5661.
107. Nacson J, Kraus JJ, Bernhardt AJ, Clausen E, Feng W, Wang Y, Nicolas E, Cai KQ, Tricarico R, Hua X, DiMarcantonio D, Martinez E, Zong D, **Handorf EA**, Bellacosa A, Testa JR, Nussenzweig A, Gupta GP, Sykes SM, Johnson N. BRCA1 mutation-specific responses to 53BP1 loss-induced homologous recombination and PARP inhibitor resistance. *Cell Reports*. 2018;24(13):3513-27.e7.
108. Semenova G, Stepanova DS, Dubyk C, **Handorf E**, Deyev SM, Lazar AJ, Chernoff J. Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis. *Oncogene*. 2017;36(38):5421-31.
109. Bobrov E, Skobeleva N, Restifo D, Beglyarova N, Cai KQ, **Handorf E**, Campbell K, Proia DA, Khazak V, Golemis EA, Astsaturov I. Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models. *Oncotarget*. 2017;8(3):4399-409.
110. Gabitova L, Restifo D, Gorin A, Manocha K, **Handorf E**, Yang DH, Cai KQ, Klein-Szanto AJ, Cunningham D, Kratz LE, Herman GE, Golemis EA, Astsaturov I. Endogenous sterol metabolites regulate growth of EGFR/KRAS-dependent tumors via LXR. *Cell Reports*. 2015;12(11):1927-38.
111. Beck TN, Kaczmar J, **Handorf E**, Nikonova A, Dubyk C, Peri S, Lango M, Ridge JA, Serebriiskii IG, Burtness B, Golemis EA, Mehra R. Phospho-T356RB1 predicts survival in HPV-negative squamous cell carcinoma of the head and neck. *Oncotarget*. 2015;6(22):18863-74.
112. Arora S, Yan H, Cho I, Fan HY, Luo B, Gai X, Bodian DL, Vockley JG, Zhou Y, **Handorf EA**, Egleston BL, Andrade MD, Nicolas E, Serebriiskii IG, Yen TJ, Hall MJ, Golemis EA, Enders GH. Genetic variants that predispose to DNA double-strand breaks in lymphocytes from a subset of patients with familial colorectal carcinomas. *Gastroenterology*. 2015;149(7):1872-83.e9

Genetic studies

113. Serebriiskii IG, Connelly C, Frampton G, Newberg J, Cooke M, Miller V, Ali S, Ross JS, **Handorf E**, Arora S, Lieu C, Golemis EA, Meyer JE. Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients. *Nature Communications*. 2019;10(1):3722.
114. Vijayvergia N, Boland PM, **Handorf E**, Gustafson KS, Gong Y, Cooper HS, Sheriff F, Astsaturov I, Cohen SJ, Engstrom PF. Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study. *British Journal of Cancer*. 2016;115(5):564-70.

115. Taylor NJ, **Handorf EA**, Mitra N, Avril MF, Azizi E, Bergman W, Bianchi-Scarra G, Bishop DT, Bressac-de Paillerets B, Calista D, Cannon-Albright LA, Cuellar F, Cust AE, Demenais F, Elder DE, Friedman E, Gerdes AM, Ghiorzo P, Goldstein AM, Grazziotin TC, Hansson J, Hayward NK, Hocevar M, Hoiom V, Holland EA, Ingvar C, Landi MT, Landman G, Larre-Borges A, Leachman SA, Mann GJ, Nagore E, Olsson H, Palmer J, Peric B, Pjanova D, Puig S, Schmid H, van der Stoep N, Tucker MA, Wadt KAW, Whitaker L, Yang XR, Newton Bishop JA, Gruis NA, Kanetsky PA. Phenotypic and histopathological tumor characteristics according to CDKN2A mutation status among affected members of melanoma families. *The Journal of Investigative Dermatology*. 2016;136(5):1066-9.
116. Beck TN, Georgopoulos R, Shagisultanova EI, Sarcu D, **Handorf EA**, Dubyk C, Lango MN, Ridge JA, Astsaturon I, Serebriiskii IG, Burtneess BA, Mehra R, Golemis EA. EGFR and RB1 as dual biomarkers in HPV-negative head and neck cancer. *Molecular Cancer Therapeutics*. 2016;15(10):2486-97.
117. Nicolas E, Arora S, Zhou Y, Serebriiskii IG, Andrade MD, **Handorf E**, Bodian DL, Vockley JG, Dunbrack RL, Ross EA, Egleston BL, Hall MJ, Golemis EA, Giri VN, Daly MB. Systematic evaluation of underlying defects in DNA repair as an approach to case-only assessment of familial prostate cancer. *Oncotarget*. 2015;6(37):39614-33.
118. Pfeffer LM, Li K, Fleckenstein JF, Marion TN, Diament J, Yang CH, Pfeffer SR, Fan M, **Handorf E**, Handorf CR. An interferon response gene signature is associated with the therapeutic response of hepatitis C patients. *PLOS One*. 2014;9(8):e104202.
119. **Handorf E**, Crumpler N, Gross L, Giri VN. Prevalence of the HOXB13 G84E mutation among unaffected men with a family history of prostate cancer. *Journal of Genetic Counseling*. 2014;23(3):371-6.
120. McCarthy AM, Armstrong K, **Handorf E**, Boghossian L, Jones M, Chen J, Demeter MB, McGuire E, Conant EF, Domchek SM. Incremental impact of breast cancer SNP panel on risk classification in a screening population of white and African American women. *Breast Cancer Research and Treatment*. 2013;138(3):889-98.
121. Armstrong K, **Handorf EA**, Chen J, Bristol Demeter MN. Breast cancer risk prediction and mammography biopsy decisions: a model-based study. *American Journal of Preventive Medicine*. 2013;44(1):15-22.
122. Roberts KE, Kawut SM, Krowka MJ, Brown RS, Jr., Trotter JF, Shah V, Peter I, Tighiouart H, Mitra N, **Handorf E**, Knowles JA, Zacks S, Fallon MB. Genetic risk factors for hepatopulmonary syndrome in patients with advanced liver disease. *Gastroenterology*. 2010;139(1):130-9.e24.

Retrospective clinical studies

123. Schober JP, Braun A, Ginsburg KB, Bell S, Castro Bigalli AA, Chen M, Wang R, Magee D, Bukavina L, **Handorf E**, Yu JQ, Chen DYT, Greenberg RE, Smaldone MC, Viterbo R, Correa AF, Uzzo RG, Kutikov A. Clinical Performance of Technetium-99m-Sestamibi SPECT/CT Imaging in Differentiating Oncocytic Tumors from Renal Cell Carcinoma in Routine Clinical Practice. *J Urol*. 2023 Jun 28:101097JU0000000000003557. PMID: 37378576. (In press)
124. Laderman L, Sreekrishnanilayam K, Pandey RK, **Handorf E**, Blumenreich A, Sorice KA, Lynch SM, Cheema K, Nagappan L, Sosa IR, Dotan E, Vijayvergia N. Venous thromboembolism in metastatic pancreatic cancer. *Eur J Haematol*. 2023 Jun;110(6):706-714.
125. Strother M, Uzzo RN, **Handorf E**, Uzzo RG. Distinguishing lipid-poor angiomyolipoma from renal carcinoma using tumor shape. *Urol Oncol*. 2023 Feb 18:S1078-1439(23)00004-2. doi: 10.1016/j.urolonc.2023.01.008. Epub ahead of print. PMID: 36801192. (In press)
126. Liu L, Ross NM, **Handorf EA**, Meeker CR, Chen G, Baldwin D, Vijayvergia N. Incidence of asymptomatic COVID-19 positivity in cancer patients and effects on therapy. *Journal of Cancer Research in Clinical Oncology*. 2023 Jul;149(7):3243-3247.

127. Hemenway G, Lewis B, Ghatalia P, Anari F, Plimack ER, Kokate R, **Handorf E**, Deng M, Geynisman DM, Zibelman M. Neoadjuvant chemotherapy with accelerated methotrexate, vinblastine, doxorubicin, and cisplatin in patients with muscle-invasive bladder cancer: A retrospective age-stratified analysis on safety and efficacy. *European Urology Oncology*. 2023 Aug;6(4):431-436.
128. Ginsburg KB, Castro Bigalli AA, Schober JP, Perlman D, Handorf EA, Chen DYT, Greenberg RE, Viterbo R, Uzzo RG, Kutikov A, Smaldone MC, Correa AF. Association of tumor size and surgical approach with oncological outcomes and overall survival in patients with adrenocortical carcinoma. *Urol Oncol*. 2022 Oct;40(10):455.e19-455.e25.
129. Strother MC, Cho EY, Loecher M, Strauss D, Chandra A, **Handorf E**, Yu J, Chen DYT, Uzzo R, Levin L, Anaokar J, Kutikov A. The Delayed Nephrogram: Point-of-care quantitative measurement, validation as an indicator of obstruction, and novel use as a predictor of renal functional impairment. *European Urology Focus*. 2022 Feb 15;S2405-4569(22)00042-6.
130. Pirlamarla AK, Hansen CC, Deng M, **Handorf E**, Paly J, Wong JK, Hallman MA, Chen DYT, Geynisman DM, Kutikov A, Horwitz EM. Early prostate-specific antigen kinetics for low- and intermediate-risk prostate cancer treated with definitive radiation therapy. *Practical Radiation Oncology*. 2022 Jan-Feb;12(1):60-67.
131. Strother MC, Kutikov A, Epstein M, Bochner E, Deng M, **Handorf E**, Lewis B, Ghatalia P, Greenberg RE, Chen D, Viterbo R, Anari F, Smaldone MC, Zibelman MR, Uzzo RG, Plimack ER, Geynisman DM. Safety of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer and malignant ureteric obstruction. *BJU International*. 2022 Mar;129(3):364-372.
132. Gauvin G, Do-Nguyen CC, Lou J, O'Halloran EA, Selesner LT, **Handorf E**, Collins ME, Farma JM. Gastrostomy tube for nutrition and malignant bowel obstruction in patients with cancer. *Journal of the National Comprehensive Cancer Network*. 2021 Jan 6;19(1):48-56.
133. Vapiwala N, Wong JK, **Handorf E**, Paly J, Grewal A, Tendulkar R, Godfrey D, Carpenter D, Mendenhall NP, Henderson RH, Stish BJ, Vargas C, Salama JK, Davis BJ, Horwitz EM. A pooled toxicity analysis of moderately hypofractionated proton beam therapy and intensity modulated radiation therapy in early-stage prostate cancer patients. *International Journal of Radiation Oncology Biology Physics*. 2021 Feb 1:S0360-3016(21)00117-6.
134. Jain R, Shaikh T, Yee JL, Au C, Denlinger CS, **Handorf E**, Meyer JE, Dotan E. Impact of clinical markers of nutritional status and feeding jejunostomy use on outcomes in esophageal cancer patients undergoing neoadjuvant chemoradiotherapy. *Nutrients*. 2020 Oct 17;12(10):E3177.
135. Jain R, **Handorf E**, Khare V, Blau M, Chertock Y, Hall MJ. Impact of baseline nutrition and exercise status on toxicity and outcomes in phase I and II oncology clinical trial participants. *The Oncologist*. 2020 Feb;25(2):161-169.
136. Wong JK, **Handorf E**, Lee D, Jain R, Zhang E, Cooper HS, Farma JM, Dotan E, Meyer JE. Toxicity and outcomes in older versus younger patients treated with trimodality therapy for locally advanced rectal cancer. *Journal of Geriatric Oncology*. 2020 May 4:S1879-4068(19)31645-5.
137. Jain R, Yee JL, Shaikh T, Au C, **Handorf E**, Meyer JE, Dotan E. Treatment-related toxicity and outcomes in older versus younger patients with esophageal cancer treated with neoadjuvant chemoradiation. *Journal of Geriatric Oncology*. 2019.
138. West AH, Knollman H, Dugan J, Hedeker D, **Handorf EA**, Nielsen SM, Bealin LC, Goldblatt LG, Willems H, Daly MB, Afghahi A, Olopade OI, Hulick PJ, Shagisultanova E, Huo D, Obeid E, Churpek JE. Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study. *Cancer Medicine*. 2019;8(12):5609-18.

139. Wang LS, **Handorf EA**, Wu H, Liu JC, Perlis CS, Galloway TJ. Surgery and adjuvant radiation for high-risk skin adnexal carcinoma of the head and neck. *American Journal of Clinical Oncology*. 2017;40(4):429-32.
140. Wang LS, **Handorf EA**, Ridge JA, Burtness BA, Lango MN, Mehra R, Liu JC, Galloway TJ. Lymph-node-positive cutaneous nonmelanoma skin cancer: A poor-prognosis disease in need of treatment intensification. *Ear, Nose, Throat Journal*. 2017;96(7):E12-e8
141. Judd J, Zibelman M, **Handorf E**, O'Neill J, Ramamurthy C, Bentota S, Doyle J, Uzzo RG, Bauman J, Borghaei H, Plimack ER, Mehra R, Geynisman DM. Immune-related adverse events as a biomarker in non-melanoma patients treated with Programmed Cell Death 1 Inhibitors. *The Oncologist*. 2017;22(10):1232-7.
142. Shaikh T, Zaki MA, Dominello MM, **Handorf E**, Konski AA, Cohen SJ, Shields A, Philip P, Meyer JE. Patterns and predictors of failure following tri-modality therapy for locally advanced esophageal cancer. *Acta Oncologica*. 2016;55(3):303-8.
143. Rubin DJ, **Handorf EA**, Golden SH, Nelson DB, McDonnell ME, Zhao H. Development and validation of a novel tool to predict hospital readmission risk among patients with diabetes. *Endocrine Practice*. 2016;22(10):1204-15.
144. Xanthopoulos EP, **Handorf E**, Simone CB, 2nd, Grover S, Fernandes AT, Sharma S, Corradetti MN, Evans TL, Langer CJ, Mitra N, Shah A, Apisarnthanarax S, Lin LL, Rengan R. Definitive dose thoracic radiation therapy in oligometastatic non-small cell lung cancer: A hypothesis-generating study. *Practical Radiation Oncology*. 2015;5(4):e355-63.
145. Wang LS, Shaikh T, **Handorf EA**, Hoffman JP, Cohen SJ, Meyer JE. Dose escalation with a vessel boost in pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. *Practical Radiation Oncology*. 2015;5(5):e457-e63.
146. Martin JM, **Handorf EA**, Price RA, Cherian G, Buyyounouski MK, Chen DY, Kutikov A, Johnson ME, Ma CM, Horwitz EM. Comparison of testicular dose delivered by intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) in patients with prostate cancer. *Medical Dosimetry*. 2015;40(3):186-9.
147. Ginzburg S, Uzzo R, Walton J, Miller C, Kurz D, Li T, **Handorf E**, Gor R, Corcoran A, Viterbo R, Chen DY, Greenberg RE, Smaldone MC, Kutikov A. Residual parenchymal volume, not warm ischemia time, predicts ultimate renal functional outcomes in patients undergoing partial nephrectomy. *Urology*. 2015;86(2):300-5.
148. Corcoran AT, Kaffenberger SD, Clark PE, Walton J, **Handorf E**, Piotrowski Z, Tomaszewski JJ, Ginzburg S, Mehrazin R, Plimack E, Chen DY, Smaldone MC, Uzzo RG, Morgan TM, Kutikov A. Hypoalbuminaemia is associated with mortality in patients undergoing cytoreductive nephrectomy. *BJU International*. 2015;116(3):351-7

Meta-analyses and reviews

149. Chandra AA, Agarwal S, Donahue A, **Handorf E**, Abraham JA. Arthroscopic versus open management of diffuse-type tenosynovial giant cell tumor of the knee: A meta-analysis of retrospective cohort studies. *Journal of the American Academy of Orthopedic Surgeons. Global Research and Reviews*. 2021 Dec 9;4(12):e21.00217.
150. Zaorsky NG, Lehrer EJ, **Handorf E**, Meyer JE. Dose escalation in stereotactic body radiation therapy for pancreatic cancer: A meta-analysis. *American Journal of Clinical Oncology*. 2019;42(1):46-55.
151. Ghatalia P, Koenigsberg R, Pisarcik D, **Handorf EA**, Geynisman DM, Zibelman M. The evolution of clinical trials in renal cell carcinoma: A status report for 2013-2016 from the ClinicalTrials.gov website. *Kidney Cancer*. 2017;1(2):151-9.

152. Zaorsky NG, Shaikh T, **Handorf E**, Eastwick G, Hesney A, Scher ED, Jones RT, Showalter TN, Avkshtol V, Rice SR, Horwitz EM, Meyer JE. What are medical students in the United States learning about radiation oncology? Results of a multi-institutional survey. *International Journal of Radiation Oncology, Biology, Physics*. 2016;94(2):235-42.
153. Friedant AJ, **Handorf EA**, Su S, Scott WJ. Minimally invasive versus open thymectomy for thymic malignancies: Systematic review and meta-analysis. *Journal of Thoracic Oncology*. 2016;11(1):30-8
154. Zibelman M, Barth P, **Handorf E**, Smaldone MC, Kutikov A, Uzzo RG, Bilusic M, Plimack ER, Wong YN, Geynisman DM. A review of interventional clinical trials in renal cell carcinoma: a status report from the ClinicalTrials.gov WebSite. *Clinical Genitourinary Cancer*. 2015;13(2):142-9

OTHER PUBLICATIONS

Preprints/Working papers

1. **Handorf EA**, Beck JR, Correa A, Ramamurthy C, Geynisman DM. Cost-effectiveness analysis for therapy sequence in advanced cancer: A microsimulation approach with application to metastatic prostate cancer. <https://arxiv.org/abs/2210.05086>

Book chapters

2. Beck, RJ, **Handorf, EA**. Markov Modeling in Decision Analysis. Chapter 4, Pharmacoeconomics From Theory to Practice, 2nd ed. Arnold RJ. Ed. Boca Raton: CRC Press, Taylor & Francis Group, 2020.

Editorials

3. Kadow BT, Joshi SS, Kutikov A, **Handorf E**, Smaldone MC, Uzzo RG, Geynisman DM. The volume-outcome relationship in kidney cancer: is more really better? *Ann Transl Med*. 2019 Dec;7(Suppl 8):S336.
4. Cahn DB, **Handorf EA**, Smaldone MC. Bladder Extirpation vs Preservation: The Treatment Debate. *JAMA surgery*. 2018;153(10):889-90.
5. Joshi SS, **Handorf E**, Smaldone MC, Geynisman DM. What can the National Cancer Database tell us about disparities in advanced bladder cancer outcomes? *Translational andrology and urology*. 2018;7(4):732-5.
6. Murphy CT, Galloway TJ, **Handorf EA**, Egleston BL, Ridge JA. Reply to P. Blanchard et al. *Journal of clinical oncology*. 2016;34(19):2318-9.
7. Bekelman JE, Mitra N, **Handorf EA**, Uzzo RG, Hahn SM, Polsky D, et al. Reply to G. Gandaglia et al and K. Lu. *Journal of clinical oncology*. 2015;33(25):2833.
8. **Handorf EA**, Smaldone MC. Editorial comment. *Urology*. 2014;83(1):132-3.